The Interface between Depression and Alzheimer's Disease. A Comprehensive Approach

Area of Science:

• Neuroscience
• Geriatrics
• Psychiatry

Background:

• Depression and Alzheimer's disease (AD) frequently co-occur in the elderly, significantly impacting patient and caregiver quality of life.
• Late-life depression can be an early symptom or a risk factor for AD, highlighting a complex relationship.

Purpose of the Study:

• To review recent advancements in understanding the neurobiological underpinnings of depression in AD.
• To evaluate the efficacy of antidepressant treatments for depression in Alzheimer's disease patients.

Main Methods:

• Systematic review of neurobiological hypotheses, including neuroinflammation and dysimmune regulation.
• Analysis of 10 small double-blind randomized placebo-controlled trials involving 638 patients treated with various antidepressants (sertraline, mirtazapine, fluoxetine, imipramine, clomipramine, escitalopram, vortioxetine).

Main Results:

• Evidence suggests neuroinflammation and dysimmune regulation may be linked to depression in AD, while the role of amyloid deposition remains unresolved.
• Meta-analysis of clinical trials (weighted OR: 1.29; 95% CI: 0.77-2.16) showed no significant difference in antidepressant efficacy compared to placebo for depression in AD.
• Antidepressants did not negatively impact cognition as measured by the Mini-Mental State Examination (MMSE) in 18 clinical trials.

Conclusions:

• Current antidepressant treatments show controversial efficacy for depression in Alzheimer's disease patients.
• Neurobiological factors like neuroinflammation warrant further investigation.
• Alternative therapeutic strategies beyond medication require additional research.